The role of AKR1C3 or its products in hormone-dependent and prostaglandin-dependent cancers has been investigated in a number of systems including breast cancer, prostate cancer, endometrial cancer, and acute myelogenous leukemia [2], [13]–[17]. Here, AKR1C3 is linked to breast carcinoma.